In this context, comprehensive immune profiling has demonstrated that NSCLC tumors harboring KEAP1/STK11 mutations exhibit low PD-L1 expression, reduced interferon gamma signaling, and diminished infiltration of CD8+ T-cells, correlating with resistance to anti-PD-1/PD-L1 therapy despite high TMB [53,54]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.